Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway  by Ogata, Takehiro et al.
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OBJECTIVES We sought to clarify that a peroxisome proliferator-activated receptor-alpha (PPAR-alpha)
activator inhibits myocardial fibrosis and its resultant diastolic dysfunction in hypertensive
heart disease, as well as to investigate whether inflammatory mediators through the nuclear
factor (NF)-kappa-B pathway are involved in the effects.
BACKGROUND Patients with hypertensive heart disease often have diastolic heart failure without systolic
dysfunction. Meanwhile, it has been well established in atherosclerosis that PPAR-alpha
activation negatively regulates early inflammation. In hypertensive hearts, however, it is still
unclear whether PPAR-alpha activation inhibits inflammation and fibrosis.
METHODS Twenty-one rats were randomly separated into the following three groups: deoxycorticoste-
rone acetate (DOCA)-salt hypertensive rats treated with a PPAR-alpha activator, fenofibrate
(80 mg/kg/day for 5 weeks); DOCA-salt rats treated with vehicle only; and uni-
nephrectomized rats as normotensive controls.
RESULTS Fenofibrate significantly inhibited the elevation of left ventricular end-diastolic pressure and
the reduction of the magnitude of the negative maximum rate of left ventricular pressure rise
and decline, corrected by left ventricular pressure (dP/dtmax/P), which are indicators of
diastolic dysfunction. Next, fenofibrate prevented myocardial fibrosis and reduced the
hydroxyproline content and procollagen I and III messenger ribonucleic acid expression.
Finally, inflammatory gene expression associated with NF-kappa-B (interleukin-6,
cyclooxygenase-2, vascular cell adhesion molecule-1, and monocyte chemoattractant protein-
1), which is upregulated in DOCA-salt rats, was significantly suppressed by fenofibrate.
Activation of NF-kappa-B and expression of I-kappa-B-alpha in DOCA-salt rats were
normalized by fenofibrate.
CONCLUSIONS A PPAR-alpha activator reduced myocardial fibrosis and prevented the development of
diastolic dysfunction in DOCA-salt rats. The effects of a PPAR-alpha activator may be
mediated partly by prevention of inflammatory mediators through the NF-kappa-B pathway.
These results suggest that treatment with PPAR-alpha activators will improve diastolic
dysfunction in hypertensive heart disease. (J Am Coll Cardiol 2004;43:1481–8) © 2004 by
the American College of Cardiology Foundationa
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iiastolic heart failure (HF) without left ventricular (LV)
ystolic dysfunction comprises 30% to 50% of HF in clinical
ractice, and hypertensive heart disease is a major cause of
his type of HF (1). The complication of myocardial fibrosis
hould be avoided in hypertensive heart disease, because
ncreasing ventricular stiffness caused by myocardial fibrosis
eads to the development of diastolic dysfunction of the
eart. Diastolic dysfunction in patients with prolonged
ypertension is often associated with myocardial fibrosis in
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esearch Alliance at the University of Tsukuba.
Manuscript received August 28, 2003; revised manuscript received November 15,003, accepted November 18, 2003.ddition to muscular hypertrophy as a final feature of
ypertensive heart disease.
Peroxisome proliferator-activated receptors (PPARs) be-
ong to a superfamily of nuclear ligand-activated transcrip-
ion factors. The PPARs are key players in lipid and glucose
etabolism and are implicated in metabolic disorders pre-
isposing to atherosclerosis (2). At present, three major
PAR family members have been identified: PPAR-alpha is
ighly expressed in the liver and to a lesser extent in the
eart, skeletal muscle, and kidney; PPAR-gamma is pre-
ominately expressed in adipose tissue; and PPAR-delta is
biquitously expressed. Whereas PPAR-gamma promotes
ipid storage by regulating adipocyte differentiation, PPAR-
lpha stimulates beta-oxidative degradation of fatty acids.
Mice deficient in PPAR-alpha a prolonged response to
nflammatory stimuli and age-dependent myocardial fibro-
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Inhibition of Cardiac Fibrosis by PPAR-alpha Activator April 21, 2004:1481–8is, suggesting that PPAR-alpha is also a modulator of
nflammation and fibrosis (3,4). Hypolipidemic fibrate
rugs are PPAR-alpha ligands that inhibit the progressive
ormation of atherosclerotic lesions, which involves chronic
nflammatory processes (5), even in the absence of an
therogenic lipoprotein-lowering effect (6,7). Various data
uggest that fibrates inhibit the vascular inflammatory re-
ponse via PPAR-alpha by interfering with the nuclear
actor (NF)-kappa-B transactivation capacity, involving a
irect protein-protein interaction with the p65 subunit
8,9). Our preliminary study demonstrated that a PPAR-
lpha activator prevented myocardial fibrosis in the heart of
ypertrophied rats after abdominal aortic banding (10), but
e did not clarify the mechanism by which a PPAR-alpha
ctivator prevented myocardial fibrosis and whether it im-
roved diastolic dysfunction of the heart in that model.
Therefore, the purpose of this study was to examine the
ffects of a PPAR-alpha activator, fenofibrate, on myocar-
ial fibrosis and diastolic dysfunction in a deoxycorticoste-
one acetate (DOCA)-salt hypertensive rat model. The
eason we used DOCA-salt rats for the present study is that
ats with prolonged hypertension provided a more suitable
odel of human hypertensive heart disease. Furthermore, it
s important to investigate the effects of fenofibrate with
espect to the inflammatory response contributing to myo-
ardial fibrosis, because Ammarguellat et al. (11) suggested
hat activation of inflammatory mediators related to NF-
appa-B could be major components of myocardial fibrosis
n this model. Therefore, we examined the gene expression
f inflammatory cytokines that are regulated by NF-
appa-B, such as interleukin-6 (IL-6), cyclooxygenase-2
COX-2), vascular cell adhesion molecule-1 (VCAM-1),
nd monocyte chemoattractant protein-1 (MCP-1), at the
essenger ribonucleic acid (mRNA) level in this model, as
ell as the effects of a PPAR-alpha activator on both
F-kappa-B activation and I-kappa-B-alpha protein ex-
Abbreviations and Acronyms
COX-2  cyclooxygenase-2
DOCA  deoxycorticosterone acetate
DOCA-F  deoxycorticosterone acetate-salt rats
treated with fenofibrate
DOCA-V  deoxycorticosterone acetate-salt rats
treated with vehicle
dP/dtmax  maximum rate of left ventricular pressure
rise or decline
HF  heart failure
IL-6  interleukin-6
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
MCP-1  monocyte chemoattractant protein-1
NF  nuclear factor
PPAR-alpha  peroxisome proliferators-activated
receptor-alpha
UN  uni-nephrectomized control
VCAM-1  vascular cell adhesion molecule-1ression. mETHODS
nimal models and experimental designs. Twenty-one
ale Sprague-Dawley rats (weighing 160 to 180 g, age 6
eeks) were randomly separated into three groups: the first
roup comprised DOCA-salt rats treated with fenofibrate
DOCA-F) (n  8; 80 mg/kg/day by gavage; Kaken Seiyaku
td., Tokyo, Japan) in vehicle (3% arabic gum); the second
roup comprised DOCA-salt rats treated with vehicle alone
DOCA-V) (n  7); and the third group comprised only
ni-nephrectomized rats (UN control, n  6). The protocol
or the DOCA-salt rats was carried out according to the
ethod of Matsumura et al. (12); after one-week recovery
ollowing unilateral nephrectomy, rats were subcutaneously
njected with DOCA (15 mg/kg; Sigma, Tokyo, Japan)
uspended in corn oil twice a week and given 1% NaCl
rinking water for five weeks. The dose of fenofibrate used in
he present study caused sustained activation of PPAR-alpha,
ithout significant lipoprotein effects in normolipidemic rats
13). The rats’ systolic blood pressure was monitored once a
eek by a tail-cuff method. This study was approved by the
niversity of Tsukuba and conformed to the “Position of the
merican Heart Association on Research Animal Use,”
dopted by the Association in November 1984.
emodynamic studies and tissue sampling. All rats were
acrificed five weeks after surgery. A 2.0F, high-fidelity,
anometer-tipped catheter (SPR-402, Millar Instruments,
ouston, Texas) was introduced through the right carotid
rtery into the LV under pentobarbital anesthesia (50
g/kg, intraperitoneally). Tracings of LV pressure were
igitized at a rate of 1,000 samples/s with a commercial
nalog-to-digital converter (MP100WS, BIOPAC Systems
nc., Goleta, California) and a personal computer using
edicated software (Acknowledge III, Version 3, BIOPAC
ystems Inc., Goleta, California). Left ventricular end-
iastolic pressure (LVEDP) was determined as the pressure
ust before the onset of an increase in LV systolic pressure
14,15). After measurement of LV pressure, the rats were
acrificed. According to quote papers (16–18), the heart was
xcised and the ventricles were divided into the LV,
ncluding the interventricular septum, and the right ventri-
le. The ventricular samples were rinsed with cold saline,
eighed, quickly frozen in liquid nitrogen, and stored at
80°C. Left ventricular hypertrophy was evaluated by the
V wet weight to body weight ratio.
istological studies. For histologic analysis, the hearts
ere subsequently fixed in 4% paraformaldehyde and em-
edded in paraffin. Coded slices stained with Masson
richrome were microscopically evaluated for interstitial and
erivascular myocardial collagen deposition.
ydroxyproline content in myocardial extracts. The hy-
roxyproline content in myocardial extracts was measured
nd used as an index of collagen content. The apical site of
he LV below the papillary muscles was removed, immedi-
tely placed in liquid nitrogen, and stored at 80°C until
easurement of the hydroxyproline content, according to
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April 21, 2004:1481–8 Inhibition of Cardiac Fibrosis by PPAR-alpha Activatorhe method of Stegemann and Stalder (19). The results
ere calculated as hydroxyproline content per wet weight of
issue.
everse transcription-polymerase chain reaction (RT-
CR) analysis of procollagen I and III, IL-6, COX-2,
CAM-1, and MCP-1 mRNA. To evaluate whether
enofibrate ameliorates myocardial fibrosis not only at the
istologic and hydroxyproline levels but also at the molec-
lar level, we investigated mRNA expression of procollagen
and III in the LV of the three groups. Furthermore,
RNA expression of IL-6, COX-2, VCAM-1, and
CP-1 was determined. The mRNA expression of
lyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
lso determined as an internal control. Total RNA from the
V was isolated by the method of acid guanidinium
hiocyanate/phenol/chloroform extraction with ISOGEN
Nippon Gene Ltd., Tokyo, Japan), according to methods
escribed in our previous reports (16–18) . Semiquantitative
T-PCR was also performed according to our previous
rticle (20). The sequences of the specific primers were as
ollows: procollagen I (sense): 5CATAAAGGGT-
ATCGTGGCTTC3; procollagen I (antisense): 5GT-
ATAGGTGATGTTCTGGGAG3; procollagen III
sense): 5GTGACAGAGGTGAAAGAGGATC3; pro-
ollagen III (antisense): 5CTGTCTTGCTCCATTCAC-
AGT3; IL-6 (sense): 5GTATGAACAGCGAT-
ATGC3; IL-6 (antisense): 5CATATTGCCAGT-
CTTCGTA3; COX-2 (sense): 5GTATGACACAA-
AGCCCATCTC3; COX-2 (antisense): 5CTTGTCA-
AACCCCCTCCAATT3; VCAM-1 (sense): 5CCT-
AACTCCTTGCACTCTACT3; VCAM-1 (antisense):
CAACAGTCAGTCCAAGCAACAC3; MCP-1
sense): 5ACCTGCTGCTACTCATTCACTG3;
CP-1 (antisense): 5GTGGTTGTGGAAAAGAGA-
TGG3; GAPDH (sense): 5GCCATCAACGAC-
CCTTCATTG3; GAPDH (antisense): 5TGC-
AGTGAGCTTCCCGTTC3.
Polymerase chain reaction was performed with the an-
ealing temperature and required cycles for each template as
ollows: 59°C for procollagen I, 62°C for procollagen III,
2°C for IL-6, 59°C for COX-2, 61°C for VCAM-1, 62°C
or MCP-1, and 62°C for GAPDH. The amplified prod-
cts on agarose gel were stained with ethidium bromide,
isualized with a ultraviolet transilluminator, and photo-
raphed. The photographs were scanned (CanoScan 600,
anon Ltd., Tokyo, Japan), and quantification was per-
ormed with MacBAS (Fuji Film Ltd., Tokyo, Japan).
etection of NF-kappa-B activation. To determine NF-
appa-B activity, we used a BD Mercury TransFactor kit (BD
iosciences Clontech, Tokyo, Japan). Using an ELISA-based
ormat, the TransFactor kit detected DNA binding by specific
ranscription factors (21). The consensus binding sequence for
he NF-kappa-B p65 subunit was GGGGTATTTCC (22).
bsorbance was measured at 655 nm with a microplate reader
Biolumin 960, Molecular Dynamics, Inc., Sunnyvale, Califor-
ia). Five rats in each group were used, and 100 g nuclear 1rotein was applied for each sample. Nuclear proteins were
solated from the heart to estimate NF-kappa-B translocation.
n short, 70 mg of LV from heart tissue was homogenized in
ce-cold Tris-buffered saline and centrifuged at 3,000g for 5
in at 4°C. The pellet was resuspended by gentle pipetting in
.8 ml of ice-cold hypotonic buffer containing 10 mmol/l
EPES, pH 7.9, 10 mmol/l KCl, 0.1 mmol/l EDTA, 0.1
mol/l EGTA, 1 mmol/l dithiothreitol, 0.5 mmol/l phenyl-
ethane sulfonyl fluoride, 50 mmol/l NaF, 30 mmol/l beta-
lycerolphosphate, 1 mmol/l Na3VO4, and 10 g/ml each of
protinin, pepstatin, and leupeptin. The solution was allowed
o swell on ice for 15 min after addition of 100 l of 10%
onidet P-40 (Wako, Osaka, Japan), and the tube was
ortexed vigorously for 45 s. The homogenate was centrifuged
or 30 s at 4°C in a microcentrifuge tube. The supernatant
ontaining cytoplasmic protein was stored at 80°C. The
uclear pellet was resuspended in a solution containing 20
mol/l HEPES, pH 7.9, 0.4 mol/l NaCl, 1 mmol/l EDTA,
mmol/l EGTA, 1 mmol/l DTT, 1 mmol/l PMSF, and 10
g/ml each of aprotinin, pepstatin, and leupeptin. The tubes
ere shaken vigorously at 4°C for 30 min on a shaking
latform. The nuclear extracts were stored at 70°C. The
rotein concentration was estimated using a Pierce protein
ssay kit (Wako, Osaka, Japan).
estern blot analysis of I-kappa-B-alpha. Cytoplasmic
roteins (10 g) from each sample were mixed with sodium
odecyl sulfate polyacrylamide gel (SDS-PAGE) sample
uffer containing 62 mmol/l Tris, pH 6.8, 10% glycerol, 2%
DS, 5% beta-mercaptoethanol, and 0.003% bromophenol
lue, heated at 95°C for 5 min and separated by 12.5%
DS-PAGE electrophoresis. The proteins were transferred
nto Immobilon transfer membranes (Millipore, Tokyo,
apan). The I-kappa-B proteins were detected using
-kappa-B-alpha antibody (New England Biolabs, Tokyo,
apan), horseradish peroxidase-conjugated goat anti-rabbit
mmunoglobulin G (Amersham, Tokyo, Japan) and En-
anced ChemiLuminescence (ECL plus from Amersham)
eagents.
tatistical analysis. All data are expressed as the mean
alue  SEM. One-way analysis of variance followed by
onferroni correction for post hoc tests was used for
tatistical comparison among the various treatment groups.
ll statistical comparisons were performed with StatView
ersion 5.0 for Windows (SAS Institute Inc., Cary, North
arolina). Values of p  0.05 were considered statistically
ignificant.
ESULTS
ystolic blood pressure, body weight, and heart weight of
ats. Time-related changes in systolic blood pressure for
he three groups are shown in Figure 1. Systolic blood
ressure in DOCA-V and DOCA-F rats was elevated to a
imilar degree after two weeks and was significantly higher
han that in UN control rats after four weeks (184 10 and
78  6 vs. 144  5 mm Hg, respectively; p  0.01). Body
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Inhibition of Cardiac Fibrosis by PPAR-alpha Activator April 21, 2004:1481–8eight was similar in UN control and DOCA-salt rats and
as unaffected by administration of fenofibrate. Body
eight-corrected LV mass was significantly increased in
OCA-V and DOCA-F rats compared with UN control
ats, and there was no difference in LV mass between
OCA-F and DOCA-V rats (Table 1).
ffects of fenofibrate on hemodynamics in DOCA-salt
ats. We measured the negative or positive maximum
ate of LV pressure rise or decline (dP/dtmax), the value
orrected by the corresponding LV pressure (dP/dtmax/
), and LVEDP in the three groups (Table 2). The
OCA-V rats had a significant decrease in dP/dtmax/P
nd a significant increase in LVEDP, as compared with
N control rats (p  0.01). These parameters were
mproved by fenofibrate treatment (p  0.01 vs. DOCA-
). The values of dP/dtmax/P were similar among the
hree groups.
ffects of fenofibrate on collagen deposition and procol-
agen I and III mRNA expression in the LV of DOCA-
alt rats. Figure 2 shows representative photomicro-
raphs of the myocardium of rats in the UN control,
OCA-V, and DOCA-F groups. There appears to be an
ncrease in interstitial and perivascular collagen deposi-
igure 1. Time-related changes in systolic blood pressure of uni-
ephrectomized control rats (UN control) (n  6), deoxycorticosterone
cetate-salt rats treated with vehicle (DOCA-V) (n  7), and deoxycor-
icosterone acetate-salt rats treated with fenofibrate (DOCA-F) (n  8)
ats. Data are expressed as the mean value  SEM. **p  0.01 vs. UN
ontrol.
able 1. Body and Heart Weights of Deoxycorticosterone
cetate-Salt Rats Treated With the Peroxisome Proliferator-
ctivated Receptor-Alpha Activator, Fenofibrate
UN control
(n  6)
DOCA-V
(n  7)
DOCA-F
(n  8)
W (g) 414  8 388  24 409  14
VW (mg) 845  23 1,100  51* 1,070  53*
VW (mg) 230  7 217  11 245  15
VW/BW (mg/g) 2.04  0.04 2.88  0.16* 2.63  0.13*
VW/BW (mg/g) 0.56  0.01 0.56  0.02 0.60  0.03
p  0.01 vs. UN control. Data are presented as the mean value  SEM.
BW  body weight; DOCA-F  DOCA-salt hypertensive rats treated with
enofibrate; DOCA-V  deoxycorticosterone acetate–salt hypertensive rats treated
ith vehicle; LVW left ventricular wet weight; RVW right ventricular wet weight;pN control  uni-nephrectomized control rats.ion in DOCA-V compared with UN control rats.
reatment with fenofibrate clearly prevented collagen
eposition in DOCA-salt rats. These findings were
onfirmed by analyzing the hydroxyproline content. Fig-
re 3 shows the hydroxyproline content and levels of
rocollagen I and III mRNA in the LV of each group,
oth of which were 1.6- to 1.9-fold higher in DOCA-V
han in UN control rats (p  0.05). In DOCA-F rats, the
ydroxyproline content and levels of procollagen I and III
RNA were significantly reduced compared with those
n DOCA-V rats (4.68  0.21 vs. 3.62  0.40 mol/g,
.86  0.22 vs. 1.11  0.35 U, 1.61  0.12 vs. 1.13 
.12 U, respectively; p  0.05 vs. DOCA-V).
ffects of fenofibrate on IL-6, COX-2, VCAM-1, and
CP-1 mRNA expression in the LV of DOCA-salt
ats. Figure 4 shows levels of IL-6, COX-2, VCAM-1, and
CP-1 mRNA in each group. The inflammatory gene
xpression levels in the LV were significantly higher in
OCA-V than in UN control rats (p  0.05). In DOCA-F
ats, levels of IL-6, COX-2, VCAM-1, and MCP-1 mRNA
ere significantly lower than in DOCA-V rats (7.50  1.34
s. 4.01  0.78, 2.62  0.25 vs. 1.20  0.87, 1.89  0.16 vs.
.11  0.22, and 5.17  1.02 vs. 2.55  0.51 U, respectively;
 0.05 vs. DOCA-V).
he DNA binding activity of NF-kappa-B and I-kappa-
-alpha protein levels in the LV of DOCA-salt rats.
ecause inflammatory gene expression interferes with NF-
appa-B activation, and a PPAR-alpha activator
pregulates NF-kappa-B activity, we measured the DNA
inding activity of NF-kappa-B using the NF-kappa-B
onsensus binding sequence (Fig. 5A). Activation of NF-
appa-B in DOCA-V rats was significantly higher than that
n UN control rats (p  0.05). In DOCA-salt rats treated
ith fenofibrate, NF-kappa-B activation returned to the
asal level of UN control rats (0.118  0.003 vs. 0.100 
.005 optical density; p  0.05 vs. DOCA-V). Figure 5B
hows a representative example of I-kappa-B-alpha protein in
ach group assessed by Western blotting. Expression of
-kappa-B-alpha was clearly suppressed in DOCA-V com-
able 2. Hemodynamics in Deoxycorticosterone Acetate-Salt
ats Treated With the Peroxisome Proliferator-Activated
eceptor-Alpha Activator, Fenofibrate
UN Control DOCA-V DOCA-F
ystolic BP (mm Hg) 135  9 178  10* 161  13
dP/dtmax (mm Hg/s) 4,298  428 4,848  336 4,251  217
dP/dtmax (mm Hg/s) 3,497  322 4,085  327 3,178  521
dP/dtmax/P (1/s) 58.0  3.4 54.4  1.8 53.1  1.0
dP/dtmax/P (1/s) 39.3  1.2 32.1  0.9† 37.5  0.8‡
VEDP (mm Hg) 3.4  0.4 6.9  0.5† 4.7  0.3*‡
p  0.05 vs. UN control, †p  0.01 vs. UN control, ‡p  0.01 vs. DOCA-V. Data
re presented as the mean value  SEM.
BP  blood pressure; dP/dtmax  positive or negative maximum rate of rise and
all of left ventricular pressure; dP/dtmax/P  dP/dtmax corrected by correspond-
ng left ventricular pressure; LVEDP  left ventricular end-diastolic pressure; other
bbreviations as in Table 1.ared with UN control rats. The protein expression in
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April 21, 2004:1481–8 Inhibition of Cardiac Fibrosis by PPAR-alpha ActivatorOCA-F rats returned to the basal level. Similar results of
igure 5B were obtained from three independent experiments.
ISCUSSION
he present study demonstrated that long-term treatment
ith a PPAR-alpha activator, fenofibrate, prevented the
levation of LVEDP and the development of diastolic HF
igure 2. Interstitial and perivascular collagen deposition in the myocardial
egion of the left ventricle, as demonstrated by Masson trichrome staining.
a, b) UN control; (c, d) DOCA-V; and (e, f) DOCA-F. Bar indicates 500
m (left) or 100 m (right). Abbreviations as in Figure 1.
igure 3. Effects of peroxisome proliferators-activated receptor-alpha activ
mRNA) expression in DOCA-salt hypertensive rats. The hydroxyproline
ompared among the three groups: UN control (n  6), DOCA-V (n
everse-transcription polymerase chain reaction, and procollagen mRN
GAPDH). The DOCA-F results are compared with UN control or DOC
.01 vs. UN control, †p  0.05 vs. DOCA-V. Abbreviations as in Figure 1.n DOCA-salt hypertensive rats. In this model, no preven-
ive effects on heart weight and LV systolic function were
rovided by fenofibrate. However, perivascular and intersti-
ial collagen deposition was clearly reduced. Procollagen I
nd III mRNA levels, which were increased in the heart,
ere also reduced by fenofibrate. Furthermore, mRNA
xpression of IL-6, COX-2, VCAM-1, and MCP-1, which
s upregulated in DOCA-salt rats, was significantly sup-
ressed by fenofibrate. Activation of NF-kappa-B and the
rotein concentration of I-kappa-B-alpha in DOCA-salt
ats were also normalized by fenofibrate. The present study
uggests that activation of inflammatory mediators via the
F-kappa-B pathway is an important cause of myocardial
brosis in this model.
elationship of myocardial fibrosis and diastolic dysfu-
ction. Burlew and Weber (23) pointed out the impor-
ance of myocardial fibrosis as a cause of diastolic dysfunc-
ion. Myocardial fibrosis has been demonstrated in the
ostmortem human heart and in endomyocardial biopsy
issue in hypertensive heart disease. The amount of collagen
resent in the myocardium has also been reported to
epresent the most significant factor related to echocardio-
raphic demonstration of diastolic dysfunction in hyperten-
ive heart disease (24). In an in vivo study, Brilla et al. (25)
lso demonstrated a close relationship between myocardial
brosis and myocardial diastolic dysfunction in genetic
ypertensive rats with HF. The present study demonstrated
oth myocardial fibrosis and myocardial diastolic dysfunc-
ion in the heart of DOCA-salt hypertensive rats. These
n the hydroxyproline content and procollagen messenger ribonucleic acid
nt (A) and expression of procollagen I (B) and III (C) mRNA levels are
), and DOCA-F (n  8). Expression of mRNA was determined by
pression was corrected by glyceraldehyde-3-phosphate dehydrogenase
and shown as the mean value  SEM. *p  0.05 vs. UN control, **p ator o
conte
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he development of diastolic HF.
In the present study, fenofibrate administration inhibited
he elevation of LVEDP in DOCA-salt hypertensive rats.
glarz et al. (26) recently reported in their study that
OCA-salt and fenofibrate did not affect LVEDP in rats.
heir observations, however, were made after DOCA-salt
reatment for only three weeks. The duration of their study
s considered to be too short to elevate LVEDP. We
erformed our study after five weeks.
yocardial fibrosis is not constantly associated with LV
ypertrophy. In the present study, LV hypertrophy was
ound in both groups of DOCA-V and DOCA-F rats, but
yocardial fibrosis was dominant only in DOCA-V rats.
he present data suggest that myocardial hypertrophy itself
igure 4. Effects of peroxisome proliferators-activated receptor-alpha ac-
ivator on messenger ribonucleic acid (mRNA) expression of interleukin
IL)-6 (A), cyclooxygenase (COX)-2 (B), vascular cell adhesion molecule
VCAM)-1 (C), and monocyte chemoattractant protein (MCP)-1 (D) in
he left ventricle of deoxycorticosterone acetate-salt hypertensive rats. For
ach, the mRNA levels are compared among three groups: UN control (n
6), DOCA-V (n  7), and DOCA-F (n  8). Each column and bar
epresent the mean value  SEM. *p  0.05 vs. UN control, **p  0.01
s. UN control, †p  0.05 vs. DOCA-V, ††p  0.01 vs. DOCA-V.
bbreviations as in Figure 1.oes not necessarily induce deposition of collagen in the vyocardium. Nicoletti and Michel (27), in their review,
rgued that cardiomyocyte hypertrophy and the develop-
ent of fibrosis in hypertensive heart disease are indepen-
ent phenomena.
elationship between myocardial fibrosis and infla-
mation. In several fibrotic processes, the role of inflam-
ation has been clearly demonstrated. Several hypertension
odels revealed that perivascular fibrosis was often associ-
ted with inflammatory cell infiltration around small arteries
n the myocardium (27). Profibrogenic cytokines are indeed
eleased by inflammatory cells (28). Increased wall tension
istributed throughout the whole coronary arterial tree may
e involved in the extravasation of inflammatory cells
round vessels, and then various cytokines from infiltrating
ells, such as macrophages, become a trigger for perivascular
nd interstitial fibrosis. Morphologically, Hinglais et al. (29)
emonstrated in the myocardium of hypertensive rats that
nterstitial fibroblasts expressing procollagen mRNA were
ocalized near macrophages that infiltrated the myocardium.
ince Shahar et al. (30) demonstrated that fibroblast pro-
iferation in human interstitial lung disease was related to
L-6, inflammatory cells, such as macrophages and lympho-
ytes, may release cytokines that can act on cardiac resident
nterstitial fibroblasts.
he PPAR-alpha activator attenuates myocardial fibrosis
y preventing inflammation. It has been generally accepted
hat NF-kappa-B is an early transcriptional factor that mod-
lates gene expression in various situations requiring a rapid
nflammatory response (31). For example, NF-kappa-B acti-
igure 5. Effects of peroxisome proliferators-activated receptor-alpha ac-
ivator on nuclear factor (NF)-kappa-B activation and I-kappa-B-alpha
xpression in deoxycorticosterone acetate-salt hypertensive rats. (A) The
F-kappa-B binding activity in the left ventricle of deoxycorticosterone
cetate-salt rats. Binding specificity was assessed using an ELISA-based
ormat, as described in the Methods. Absorbance was measured at 655 nm.
ata are expressed as the mean value  SEM. *p  0.05 vs. UN control,
p  0.05 vs. DOCA-V. (B) Representative Western blots of I-kappa-B-
lpha protein in the left ventricle of UN control, DOCA-V, and DOCA-F
ats. Abbreviations as in Figure 1.ates numerous genes, including those for adhesion molecules
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April 21, 2004:1481–8 Inhibition of Cardiac Fibrosis by PPAR-alpha Activatornvolved in recruitment of circulating leukocytes to sites of
nflammation. The prototypic inducible form of NF-kappa-B
s a heterodimer composed of p50 (NF-kappa-B1) and p65
Rel A) subunits, which both belong to the NF-kappa-B/Rel
amily of proteins. Inactive NF-kappa-B is present in the
ytoplasm complexed with the inhibitory protein I-kappa-B-
lpha. Nuclear factor-kappa-B is activated by a number of
ncoming signals from the cell surface. When released from
-kappa-B-alpha by phosphorylation via activation of
-kappa-B kinase, NF-kappa-B translocates to the nucleus and
inds to the kappa-B motif of the target gene, which in turn
auses activation of several factors involved in inflammatory
esponses.
Delerive et al. (32) demonstrated that PPAR-alpha activa-
ors induced the expression of I-kappa-B-alpha in human
ortic smooth muscle cells, and they agued that the increase of
-kappa-B-alpha inhibits NF-kappa-B translocation to the
ucleus and binding to the kappa-B motif. Staels et al. (2) also
eported in human aortic smooth muscle cells that PPAR-
lpha activation inhibits cytokine-induced activation of a num-
er of inflammatory genes, such as VCAM-1, COX-2, and
L-6, by negatively interfering with NF-kappa-B transcrip-
ional activity (33). Furthermore, Watanabe et al. (4) recently
eported the development of myocardial fibrosis in PPAR-
lpha-null mice. Therefore, we hypothesized that PPAR-alpha
ctivators may prevent inflammation through the NF-kappa-B
athway and myocardial stiffness caused by fibrosis. In the
resent study, we tried to confirm this speculation in the
ressure-overloaded heart of DOCA-salt rats. Activation of
F-kappa-B was increased in the heart of DOCA-salt rats,
nd there was upregulated mRNA expression of COX-2,
CAM-1, MCP-1, and IL-6. Furthermore, a PPAR-alpha
ctivator, fenofibrate, attenuated NF-kappa-B nuclear binding
ctivity and normalized cytoplasmic I-kappa-B-alpha protein
xpression.
tudy limitations. As a limitation of this study, it should be
ointed out that another mechanism exists in myocardial
brosis besides inflammatory responses through the NF-
appa-B signaling pathway. We previously reported that fe-
ofibrate treatment inhibited endothelin-1 mRNA levels in a
odel of aortic banding in rats (10). This result suggests that
he PPAR-alpha activator may inhibit myocardial fibrosis by
uppressing endothelin-1 production. However, the NF-
appa-B signaling pathway may have an independent associ-
tion with the effect of endothelin-1, because endothelin-1
oes not stimulate the NF-kappa-B pathway directly.
onclusions. We demonstrated that prolonged hyperten-
ion induced myocardial fibrosis and diastolic dysfunction
diastolic HF), and that these disorders were clearly pre-
ented by treatment with fenofibrate. From molecular
nalyses, we concluded that the effects of fenofibrate were
ependent on inhibition of the inflammatory response
hrough the NF-kappa-B pathway. Therapy with PPAR-
lpha activators in patients with hypertensive heart disease
ay provide a new therapeutic strategy against the finalevelopment of diastolic HF in this disorder.cknowledgments
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